Waardenburg syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:3440OMIM:148820E70.3
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Waardenburg syndrome (WS) is a group of inherited conditions characterized by varying degrees of sensorineural hearing loss and pigmentary abnormalities of the hair, skin, and eyes. It is named after Dutch ophthalmologist Petrus Johannes Waardenburg, who first described the condition in 1951. The syndrome accounts for approximately 2–5% of all cases of congenital deafness. Waardenburg syndrome is classified into four main types: Type I (WS1) features dystopia canthorum (widely spaced inner corners of the eyes) along with pigmentary changes and hearing loss; Type II (WS2) lacks dystopia canthorum but otherwise shares similar features; Type III (Klein-Waardenburg syndrome) includes upper limb abnormalities in addition to the features of Type I; and Type IV (Waardenburg-Shah syndrome) combines features of Waardenburg syndrome with Hirschsprung disease (aganglionic megacolon). The condition primarily affects the auditory system, integumentary system (skin, hair), and eyes. Key clinical features include congenital sensorineural hearing loss (which can be unilateral or bilateral and ranges from mild to profound), heterochromia iridis (eyes of different colors) or brilliant blue eyes, a white forelock (poliosis) or premature graying of the hair, and patchy depigmentation of the skin (leukoderma). Dystopia canthorum and a broad nasal root are characteristic craniofacial features, particularly in Types I and III. The syndrome results from mutations in several genes involved in the development of neural crest-derived melanocytes, including PAX3 (Types I and III), MITF and SNAI2 (Type II), and EDN3, EDNRB, and SOX10 (Type IV). There is currently no cure for Waardenburg syndrome, and management focuses on addressing individual symptoms. Early identification and intervention for hearing loss is critical and may include hearing aids or cochlear implants. Genetic counseling is recommended for affected individuals and their families. Patients with Type IV require evaluation and potential surgical management for Hirschsprung disease. Dermatologic concerns related to depigmentation can be addressed with cosmetic approaches and sun protection. Regular ophthalmologic and audiologic follow-up is advised throughout life.

Clinical phenotype terms— hover any for plain English:

White forelockHP:0002211Congenital sensorineural hearing impairmentHP:0008527Blue iridesHP:0000635
Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Waardenburg syndrome.

View clinical trials →

No actively recruiting trials found for Waardenburg syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Waardenburg syndrome community →

No specialists are currently listed for Waardenburg syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Waardenburg syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Waardenburg syndromeForum →

No community posts yet. Be the first to share your experience with Waardenburg syndrome.

Start the conversation →

Latest news about Waardenburg syndrome

No recent news articles for Waardenburg syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Waardenburg syndrome

What is Waardenburg syndrome?

Waardenburg syndrome (WS) is a group of inherited conditions characterized by varying degrees of sensorineural hearing loss and pigmentary abnormalities of the hair, skin, and eyes. It is named after Dutch ophthalmologist Petrus Johannes Waardenburg, who first described the condition in 1951. The syndrome accounts for approximately 2–5% of all cases of congenital deafness. Waardenburg syndrome is classified into four main types: Type I (WS1) features dystopia canthorum (widely spaced inner corners of the eyes) along with pigmentary changes and hearing loss; Type II (WS2) lacks dystopia canthor

At what age does Waardenburg syndrome typically begin?

Typical onset of Waardenburg syndrome is neonatal. Age of onset can vary across affected individuals.